No records
|
28 |
Lubis A.M., Maruanaya S., Tantri A.R., Pontoh L.A.P., Ifran N.N.P.P.S. |
57391310600;57217187200;57188933853;57192907426;56091403800; |
The Use of Combination Paracetamol and Ibuprofen in Postoperative Pain after Total Knee Arthroplasty, a Randomized Controlled Trial |
2021 |
Pain physician |
24 |
8 |
|
E1199 |
E1204 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121993999&partnerID=40&md5=0b79df4a67066c8ba9a1818d9c6e9920 |
Department of Orthopedic & Traumatology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, DKI Jakarta, Indonesia; Universitas PattimuraMaluku, Indonesia; Department of Anesthesiology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, DKI Jakarta, Indonesia; Department of Orthopedic, Fatmawati General Hospital, DKI Jakarta, Indonesia; Department of Orthopedic & Traumatology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, DKI Jakarta, Indonesia |
Lubis, A.M., Department of Orthopedic & Traumatology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, DKI Jakarta, Indonesia; Maruanaya, S., Universitas PattimuraMaluku, Indonesia; Tantri, A.R., Department of Anesthesiology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, DKI Jakarta, Indonesia; Pontoh, L.A.P., Department of Orthopedic, Fatmawati General Hospital, DKI Jakarta, Indonesia; Ifran, N.N.P.P.S., Department of Orthopedic & Traumatology, Cipto Mangunkusumo General Hospital, Universitas Indonesia, DKI Jakarta, Indonesia |
BACKGROUND: Adequate pain management has an important role in supporting early ambulation after total knee arthroplasty (TKA). Multimodal analgesia is one of the modalities of overcoming postoperative pain. The use of a combination of paracetamol and ibuprofen is expected to reduce the total morphine requirement after TKA. OBJECTIVES: The use of a combination of paracetamol and ibuprofen to reduce morphine requirement after TKA, to provide adequate pain management and early ambulation. STUDY DESIGN: Patients scheduled for total knee arthroplasty who met the requirements for inclusion criteria were consented and randomized using randomizer.org in a 1:1:1 ratio to receive either combination paracetamol iv and ibuprofen iv (Group II), paracetamol iv only (Group II), or ibuprofen iv only (III). SETTING: Thirty-six patients aged 63-68 years who underwent TKA were included in this study. METHODS: All patients were divided into 3 groups. Group I received paracetamol 1 g and ibuprofen 800 mg, group II received 1 g paracetamol iv and 100 mL normal saline, group III received 800 mg ibuprofen iv and 100 mL normal saline, 10 minutes before the end of surgery and every 6 hours up to 24 hours. Total morphine consumption, pain score (resting, walking, knee flexion), and 2 minute-length walking tests were measured in hour 24 postoperative. Data were analyzed with SPSS 16.0. RESULTS: Median of total morphine consumption between 3 groups respectively was 7.5 (3.0-36.0) mg vs 15.0 (4.5-28.5) mg vs 9.0 (0.0-24.0) mg with no difference (P = 0.391). Mean of pain score at walking phase respectively was 4.8 ± 0.5 vs 7.3 ± 1.2 vs 5.6 ± 0.5 (hour 24, P < 0.01). Medians of 2-Minute Walking Test respectively were 6.0 (2-16) meters vs 0.0 (0-4) meters vs 0.0 (0-4) meters (hour 24, P < 0.01). LIMITATIONS: The total morphine requirement measured in this study illustrates the consumption of morphine in resting phase. CONCLUSION: The combination of paracetamol and ibuprofen is better in reducing the total morphine requirement after TKA when compared with the administration of paracetamol injection alone or ibuprofen injection alone. Combination paracetamol injection and ibuprofen injection also provides adequate pain management in order to help early ambulation. |
ibuprofen; morphine consumption; pain score; paracetamol; TKA; Multimodal analgesia |
ibuprofen; morphine; narcotic analgesic agent; paracetamol; controlled study; double blind procedure; human; knee replacement; postoperative pain; randomized controlled trial; Acetaminophen; Analgesics, Opioid; Arthroplasty, Replacement, Knee; Double-Blind Method; Humans; Ibuprofen; Morphine; Pain, Postoperative |
NLM (Medline) |
21501149 |
|
34793640 |
Article |
Q1 |
1310 |
2852 |
|
|
66 |
Pranata R., Yonas E., Huang I., Lim M.A., Nasution S.A., Kuswardhani R.A.T. |
57201973901;57201987097;57208576645;57216039756;57189373134;36863900500; |
Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis |
2021 |
European journal of gastroenterology & hepatology |
33 |
1S Suppl 1 |
|
e368 |
e374 |
|
8 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107230733&doi=10.1097%2fMEG.0000000000002091&partnerID=40&md5=ea06112f412d95910a1757cc5756c08a |
Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Faculty of Medicine, Universitas YARSIJakarta, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia; Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo National General HospitalJakarta, Indonesia; Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Udayana University, Sanglah Teaching Hospital, Indonesia |
Pranata, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Yonas, E., Faculty of Medicine, Universitas YARSIJakarta, Indonesia; Huang, I., Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia; Lim, M.A., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Nasution, S.A., Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo National General HospitalJakarta, Indonesia; Kuswardhani, R.A.T., Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Udayana University, Sanglah Teaching Hospital, Indonesia |
BACKGROUND/AIMS: In this meta-analysis, we aimed to evaluate the prognostic value of fibrosis-4 index (FIB-4) in COVID-19. METHODS: We performed a comprehensive literature search of PubMed, Embase, and Scopus databases on 26 November 2020. FIB-4 was calculated by [age (years) × AST (IU/L)]/[platelet count (109/L) × √ALT (U/L)]. A value above cutoff point was considered high and a value below cutoff point was considered low. The main outcome was mortality, the association between high FIB-4 and mortality was reported in odds ratio (OR). Sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic OR (DOR), area under the curve (AUC) were generated. RESULTS: There were 963 patients from five studies included in this systematic review and meta-analysis. Meta-analysis showed that high FIB-4 was associated with increased mortality [OR 3.96 (2.16-7.27), P < 0.001; I2: 41.3%]. High FIB-4 was associated mortality with a sensitivity of 0.56 (0.40-0.70), specificity of 0.80 (0.72-0.86), PLR 2.8 (1.8-4.2), NLR 0.55 (0.39-0.78), DOR 5 (2-10), and AUC of 0.77 (0.73-0.81). Fagan's nomogram indicated that for a pre-test probability (mortality) of 30%, a high FIB-4 was associated with 54% post-test probability and a low FIB-4 was associated with 19%, respectively. The funnel-plot analysis was asymmetrical, trim-and-fill analysis by imputation of a study on the left side using linear estimator resulted in an OR of 3.48 (1.97-6.14). Egger's test showed no indication of small-study effects (P = 0.881). CONCLUSION: High FIB-4 was associated with mortality in patients with COVID-19. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. |
|
area under the curve; fibrosis; human; meta analysis; platelet count; Area Under Curve; COVID-19; Fibrosis; Humans; Platelet Count; SARS-CoV-2 |
NLM (Medline) |
14735687 |
|
35048648 |
Article |
#N/A |
#N/A |
#N/A |
|
|
91 |
Renaldi K., Simadibrata M., Rahadiani N., Handjari D.R., William A., Sinuraya F., Makmun D. |
57190963547;23499598400;16426455700;56160657900;57209025962;57212478117;16638046900; |
Prognostic Value of COX-2, NF-κB, and Sp1 Tissue Expressions in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis |
2021 |
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology |
32 |
11 |
|
956 |
970 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122454127&doi=10.5152%2ftjg.2021.211106&partnerID=40&md5=869f590f4b509a9d15f5495cd1423389 |
Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo National General HospitalJakarta, Indonesia; Division of Gastroenterology and Hepato Billiary Pathology, Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia/ Cipto Mangunkusumo National Referral HospitalJakarta, Indonesia; Faculty of Medicine, Universitas IndonesiaJakarta, Indonesia |
Renaldi, K., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo National General HospitalJakarta, Indonesia; Simadibrata, M., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo National General HospitalJakarta, Indonesia; Rahadiani, N., Division of Gastroenterology and Hepato Billiary Pathology, Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia/ Cipto Mangunkusumo National Referral HospitalJakarta, Indonesia; Handjari, D.R., Division of Gastroenterology and Hepato Billiary Pathology, Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia/ Cipto Mangunkusumo National Referral HospitalJakarta, Indonesia; William, A., Faculty of Medicine, Universitas IndonesiaJakarta, Indonesia; Sinuraya, F., Faculty of Medicine, Universitas IndonesiaJakarta, Indonesia; Makmun, D., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo National General HospitalJakarta, Indonesia |
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is deadly cancer with a poor prognosis. Molecular prognostic markers are needed to predict the patient's survival. The cyclooxygenase-2 enzyme (COX-2) and its 2 major transcription factors--nuclear factorkappa B (NF-κB) and specificity protein 1 (Sp1)--are activated during inflammation caused by neoplasia. Several studies have investigated the association between the COX-2, NF-κB, and Sp1 tissue expressions with the patient's overall survival. Therefore, we conducted this systematic review and meta-analysis to evaluate those studies. METHODS: We searched for relevant articles from the MEDLINE database through June 2020. Studies were eligible if they included dichotomized tissue protein expression status and the overall survival as the outcome. We used RevMan and ProMeta programs to perform the meta-analysis. RESULTS: We identified 11 eligible studies. The meta-analysis showed that COX-2 tissue expression was associated with decreased overall survival (crude HR = 1.35; 95% CI, 1.05-1.74), although the result was not significant when controlling for other covariates. The NF-κB tissue expression was associated with decreased overall survival (crude HR = 2.18; 95% CI, 1.49-3.18), although it was not significant when controlling for other covariates. The Sp1 tissue expression showed significantly decreased overall survival even when adjusted with other covariates (aHR = 3.47; 95% CI, 1.52-7.94). The limitations included searching only for English publications and the substantial heterogeneity among the studies. CONCLUSION: COX-2, NF-κB, and Sp1 tissue expressions have the potential to be used as prognostic markers in PDAC. Further studies are still needed to clarify the associations. |
|
cyclooxygenase 2; immunoglobulin enhancer binding protein; Sp1 protein, human; transcription factor Sp1; tumor marker; human; meta analysis; metabolism; pancreas carcinoma; pancreas tumor; prognosis; tissue distribution; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cyclooxygenase 2; Humans; NF-kappa B; Pancreatic Neoplasms; Prognosis; Sp1 Transcription Factor; Tissue Distribution |
NLM (Medline) |
21485607 |
|
34872897 |
Article |
#N/A |
#N/A |
#N/A |
|
|
124 |
Bartlett A.W., Sudjaritruk T., Mohamed T.J., Anugulruengkit S., Kumarasamy N., Phongsamart W., Ly P.S., Truong K.H., Van Nguyen L., Do V.C., Ounchanum P., Puthanakit T., Chokephaibulkit K., Lumbiganon P., Kurniati N., Nik Yusoff N.K., Wati D.K., Sohn A.H., Kariminia A. |
56511395900;36538198800;46961185600;57209773680;7003549856;8885235300;9743902800;35811540200;54396225800;56732729400;57200558813;8071686900;7003974471;35564244800;36473260300;6504631866;55816676300;7006405275;6602745222; |
Identification, Management, and Outcomes of Combination Antiretroviral Treatment Failure in Adolescents With Perinatal Human Immunodeficiency Virus Infection in Asia |
2021 |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
73 |
7 |
|
e1919 |
e1926 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118283335&doi=10.1093%2fcid%2fciaa872&partnerID=40&md5=7af8cf47bd95718a30d3277b5797f9ba |
Kirby Institute, University of New South Wales, Sydney, Australia; Department of Pediatrics, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai UniversityChiang Mai, Thailand; Women and Children Hospital Kuala LumpurKuala Lumpur, Malaysia; Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Chennai Antiviral Research and Treatment Clinical Research Site, VHS-Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India; Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; National Centre for HIV/AIDS, Dermatology and Sexually Transmitted DiseasesPhnom Penh, Cambodia; Children's Hospital 1, Ho Chi Minh City, Viet Nam; National Hospital of PediatricsHanoi, Viet Nam; Children's Hospital 2, Ho Chi Minh City, Viet Nam; Chiangrai Prachanukroh HospitalChiang Rai, Thailand; Department of Pediatrics, Faculty of Medicine, Khon Kaen UniversityKhon Kaen, Thailand; Cipto Mangunkusumo-Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Hospital Raja Perempuan Zainab IIKelantan, Malaysia; Sanglah Hospital, Udayana UniversityBali, Indonesia; TREAT Asia, amfAR-the Foundation for AIDS ResearchBangkok, Thailand |
Bartlett, A.W., Kirby Institute, University of New South Wales, Sydney, Australia; Sudjaritruk, T., Department of Pediatrics, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai UniversityChiang Mai, Thailand; Mohamed, T.J., Women and Children Hospital Kuala LumpurKuala Lumpur, Malaysia; Anugulruengkit, S., Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand, Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Kumarasamy, N., Chennai Antiviral Research and Treatment Clinical Research Site, VHS-Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India; Phongsamart, W., Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; Ly, P.S., National Centre for HIV/AIDS, Dermatology and Sexually Transmitted DiseasesPhnom Penh, Cambodia; Truong, K.H., Children's Hospital 1, Ho Chi Minh City, Viet Nam; Van Nguyen, L., National Hospital of PediatricsHanoi, Viet Nam; Do, V.C., Children's Hospital 2, Ho Chi Minh City, Viet Nam; Ounchanum, P., Chiangrai Prachanukroh HospitalChiang Rai, Thailand; Puthanakit, T., Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand, Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Chokephaibulkit, K., Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; Lumbiganon, P., Department of Pediatrics, Faculty of Medicine, Khon Kaen UniversityKhon Kaen, Thailand; Kurniati, N., Cipto Mangunkusumo-Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Nik Yusoff, N.K., Hospital Raja Perempuan Zainab IIKelantan, Malaysia; Wati, D.K., Sanglah Hospital, Udayana UniversityBali, Indonesia; Sohn, A.H., TREAT Asia, amfAR-the Foundation for AIDS ResearchBangkok, Thailand; Kariminia, A., Kirby Institute, University of New South Wales, Sydney, Australia |
BACKGROUND: Combination antiretroviral therapy (cART) failure is a major threat to human immunodeficiency virus (HIV) programs, with implications for individual- and population-level outcomes. Adolescents with perinatally acquired HIV infection (PHIVA) should be a focus for treatment failure given their poorer outcomes compared to children and adults. METHODS: Data (2014-2018) from a regional cohort of Asian PHIVA who received at least 6 months of continuous cART were analyzed. Treatment failure was defined according to World Health Organization criteria. Descriptive analyses were used to report treatment failure and subsequent management and evaluate postfailure CD4 count and viral load trends. Kaplan-Meier survival analyses were used to compare the cumulative incidence of death and loss to follow-up (LTFU) by treatment failure status. RESULTS: A total 3196 PHIVA were included in the analysis with a median follow-up period of 3.0 years, of whom 230 (7.2%) had experienced 292 treatment failure events (161 virologic, 128 immunologic, 11 clinical) at a rate of 3.78 per 100 person-years. Of the 292 treatment failure events, 31 (10.6%) had a subsequent cART switch within 6 months, which resulted in better immunologic and virologic outcomes compared to those who did not switch cART. The 5-year cumulative incidence of death and LTFU following treatment failure was 18.5% compared to 10.1% without treatment failure. CONCLUSIONS: Improved implementation of virologic monitoring is required to realize the benefits of virologic determination of cART failure. There is a need to address issues related to accessibility to subsequent cART regimens, poor adherence limiting scope to switch regimens, and the role of antiretroviral resistance testing. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
adolescent; antiretroviral therapy; HIV; treatment failure |
anti human immunodeficiency virus agent; adolescent; adult; Asia; CD4 lymphocyte count; child; female; human; Human immunodeficiency virus infection; pregnancy; treatment failure; virus load; Adolescent; Adult; Anti-HIV Agents; Asia; CD4 Lymphocyte Count; Child; Female; HIV Infections; Humans; Pregnancy; Treatment Failure; Viral Load |
NLM (Medline) |
15376591 |
|
32589711 |
Article |
Q1 |
3440 |
518 |
|
|
125 |
Hermansyah T.A., Ginanjar E., Putri V.H. |
57428569000;23472616600;57428569100; |
Elevation of Cardiac Biomarkers in COVID-19 As a Major Determinant for Mortality: A Systematic Review |
2021 |
Acta medica Indonesiana |
53 |
4 |
|
385 |
396 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123568570&partnerID=40&md5=0047595d5dd32380033c242e7c79fe4c |
Faculty of Medicine Universitas IndonesiaJakarta, Indonesia |
Hermansyah, T.A., Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Ginanjar, E.; Putri, V.H. |
BACKGROUND: This study aimed to summarize the prognosis of Corona Virus Disease 2019 (COVID-19) patients with elevated troponin and N-terminal pro brain natriuretic peptide (NT-proBNP) levels and demonstrate the involvement of myocardial injury as a complication in COVID-19. METHODS: A systematic literature search was performed using several databases (PubMed, MEDLINE, PROQUEST and SCOPUS ) for studies published up to August 2020. Observational studies about the mortality outcome of COVID-19 patients who experienced cardiac injury, as defined by the elevation of serum levels of troponin, brain natriuretic peptide (BNP), with NT-proBNP or only BNP or only NT-proBNP, were included. In addition, a critical appraisal was conducted for all included studies using the Critical Appraisal for Prognostic Studies checklist published by the Centre for Evidence-Based Medicine by the University of Oxford. RESULTS: Seven retrospective observational studies fulfilled the inclusion criteria. This study found that there is a higher risk of death in COVID 19 patients with higher levels of troponin and NT-proBNP, indicating the importance of these biomarkers as determinant factors to predict in-hospital deaths. CONCLUSION: Based on the analysis, elevation of troponin and NT-proBNP levels plays an essential role in determining the patient prognosis because it is shown to be associated with in-hospital mortality. This also supports the involvement of myocardial injury as a prominent fatal complication in COVID-19. |
BNP; COVID-19; myocardial injury; NT-proBNP; prognostic factors; troponin |
biological marker; brain natriuretic peptide; peptide fragment; pro-brain natriuretic peptide (1-76); troponin; blood; human; mortality; observational study; prognosis; retrospective study; Biomarkers; COVID-19; Humans; Natriuretic Peptide, Brain; Observational Studies as Topic; Peptide Fragments; Prognosis; Retrospective Studies; SARS-CoV-2; Troponin |
NLM (Medline) |
01259326 |
|
35027485 |
Article |
Q3 |
321 |
14162 |
|
|
126 |
Saldi S.R.F., Safitri E.D., Setiati S., Ranakusuma R.W., Marsigit J., Azwar M.K., Astuti P., Sari C.Y.I., Istanti R., Yulianti M., Rumende C.M., Yunihastuti E., Susilo A., Harimurti K., Liastuti L.D., Trimartani T., Restuti R.D., Syam A.F. |
55201904000;57195934356;14325991900;57189729404;57218912589;57202798959;57436688300;57218292263;23496653300;57216405885;14325966300;57221273925;57217867079;23473513200;57204676441;57428529000;55261428300;8443384400; |
Prognostic Scoring System for Mortality of Hospitalized COVID-19 Patients in Resource-Limited Settings: A Multicenter Study from COVID-19 Referral Hospitals |
2021 |
Acta medica Indonesiana |
53 |
4 |
|
407 |
415 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123568238&partnerID=40&md5=e5654832599ee37e6d1d6dad0e5cc30c |
Clinical Epidemiology and Evidence-Based Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo HospitalJakarta, Indonesia |
Saldi, S.R.F., Clinical Epidemiology and Evidence-Based Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo HospitalJakarta, Indonesia; Safitri, E.D.; Setiati, S.; Ranakusuma, R.W.; Marsigit, J.; Azwar, M.K.; Astuti, P.; Sari, C.Y.I.; Istanti, R.; Yulianti, M.; Rumende, C.M.; Yunihastuti, E.; Susilo, A.; Harimurti, K.; Liastuti, L.D.; Trimartani, T.; Restuti, R.D.; Syam, A.F. |
BACKGROUND: Many studies identified the risk factors and prognostic factors related to in-hospital COVID-19 mortality using sophisticated laboratory tests. Cost and the availability of supporting blood tests may be problematic in resource-limited settings. This multicenter cohort study was conducted to assess the factors associated with mortality of COVID-19 patients aged 18 years and older, based on history taking, physical examination, and simple blood tests to be used in resource-limited settings. METHODS: The study was conducted between July 2020 and January 2021 in five COVID-19 referral hospitals in Indonesia. Among 1048 confirmed cases of COVID-19, 160 (15%) died during hospitalization. RESULTS: Multivariate analysis showed eight predictors of in-hospital mortality, namely increased age, chronic kidney disease, chronic obstructive pulmonary disease, fatigue, dyspnea, altered mental status, neutrophil-lymphocyte ratio (NLR) ≥ 5.8, and severe-critical condition. This scoring system had an Area-under-the-curve (AUC) of 84.7%. With cut-off score of 6, the sensitivity was 76.3% and the specificity was 78.2%. CONCLUSION: The result of this practical prognostic scoring system may be a guide to decision making of physicians and help in the education of family members related to the possible outcome. |
COVID-19; mortality; predictive score; prognostic; resource-limited settings |
clinical trial; comorbidity; health care planning; hospital; hospital mortality; human; mortality; multicenter study; patient referral; prognosis; retrospective study; sensitivity and specificity; Comorbidity; COVID-19; Health Resources; Hospital Mortality; Hospitals; Humans; Prognosis; Referral and Consultation; Retrospective Studies; SARS-CoV-2; Sensitivity and Specificity |
NLM (Medline) |
01259326 |
|
35027487 |
Article |
Q3 |
321 |
14162 |
|
|
127 |
Yunihastuti E. |
57221273925; |
Prioritizing Health Care Workers Safety: The International Year of Health and Care Workers 2021 |
2021 |
Acta medica Indonesiana |
53 |
4 |
|
371 |
373 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123567858&partnerID=40&md5=6b031d0156ba2c68eb828650dd45d00d |
Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo HospitalJakarta, Indonesia |
Yunihastuti, E., Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo HospitalJakarta, Indonesia |
Healthcare workers pose a substantial risk of acquiring COVID-19 infection during their daily works. We have seen various conditions during the pandemic, such as limited adequate personal protective equipment (PPE), accurate diagnostic tests, lack of information regarding disease management, unsupportive work environment, and excessive workload, increased the number of HCWs-infected COVID-19. Compared to the general population, the risk of COVID-19 infection was several-fold higher in HCWs.Employers and health care workers both should share the responsibility to prevent occupationally acquired infections and avoid causing harm to patients by taking reasonable precautions to prevent vaccine-preventable disease transmission.This year, WHO has launched a year-long campaign under the theme -protect, invest, together'. It highlights the urgent need to invest in health care workers, not only during COVID-19. We need to ensure that all health care workers are supported, protected, motivated, and equipped to deliver safe health care at all times, to provide a high-quality standard of care to the patients. |
COVID-19; healthcare workers; personal protective equipment; safety; vaccination |
health care personnel; human; occupational health; pandemic; protective equipment; World Health Organization; COVID-19; Health Personnel; Humans; Occupational Health; Pandemics; Personal Protective Equipment; World Health Organization |
NLM (Medline) |
01259326 |
|
35027483 |
Article |
Q3 |
321 |
14162 |
|
|
128 |
Fadrian F., Chen K., Kumalawati J., Rumende C.M., Shatri H., Nelwan E.J. |
57268114000;57428620500;6504406695;14325966300;28767986500;14527452900; |
The Validation of Drug Resistance in Pneumonia (DRIP) Score in Predicting Infections due to Drug-Resistant Pathogens in Community-acquired Pneumonia at Cipto Mangunkusumo Hospital, Jakarta, Indonesia |
2021 |
Acta medica Indonesiana |
53 |
4 |
|
416 |
422 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123567110&partnerID=40&md5=9488cfa84614808f64df6510f7925f6d |
1. Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Indonesia. 2. Division of Tropical Medicine and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, alas University - M. Djamil Hospital, Padang, Jakarta, Indonesia |
Fadrian, F., 1. Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Indonesia. 2. Division of Tropical Medicine and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, alas University - M. Djamil Hospital, Padang, Jakarta, Indonesia; Chen, K.; Kumalawati, J.; Rumende, C.M.; Shatri, H.; Nelwan, E.J. |
BACKGROUND: The emergence of drug-resistant pathogens (DRP) in recent years possibly contributes to the common problems associated with community-acquired pneumonia. However, to predict the risk of the ailment, the DRIP score is mainly applied, although no validation study has been reported in Indonesia. Therefore, the score prediction accuracy in the population, patient characteristics and germ patterns appears indefinite, particularly for Cipto Mangunkusumo Hospital, Jakarta. The purpose of this study is to determine the DRIP performance as an instrument in predicting infections due to drug-resistant pathogens (DRP) in community-acquired pneumonia at Cipto Mangunkusumo Hospital. METHODS: This research employed a cross-sectional design, where the subjects were community-acquired pneumonia patients treated between January 2019 and June 2020. In addition, adequate medical records of the participants were obtained. The condition is defined as DRP when the sputum culture results show resistance to non-pseudomonal β-lactam antibiotics, macrolides, and respiratory fluoroquinolones. Furthermore, the score performance was analyzed by determining the calibration and discrimination values, using the Hosmer-Lemeshow test and AUROC, respectively. RESULTS: A total of 254 subjects were known to have satisfied the selection criteria. These participants were categorized into DRP and non-DRP groups, with 103 (40.6%) and 151 (59.4%) patients, correspondingly. The DRIP calibration analysis using the Hosmer-Lemeshow test obtained p-value = 0.001 (p <0.05), while an AUC value of 0.759 (CI 95%, 0.702-0.810) was derived from the ROC curve. However, at a score of ≥ 4, the DRIP showed sensitivity, specificity, positive and negative predictive values of 70.9, 92.7, 86.9, and 82.3%, respectively. CONCLUSION: The DRIP score demonstrated a significant performance in predicting infections due to DRP in community-acquired pneumonia. |
community-acquired pneumonia; DRIP score; resistant pathogens |
|
NLM (Medline) |
01259326 |
|
35027488 |
Article |
Q3 |
321 |
14162 |
|
|